ArticleBMC cancer2025
Unraveling the nexus between lung cancer and rheumatoid arthritis using integrative transcriptomics and genomics.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIndividuals with rheumatoid arthritis (RA) are at a significantly increased risk of developing lung cancer (LC), with a 30%-40% higher incidence compared to the general population. Although a link between the two conditions has been established, the molecular mechanisms and genetic factors remain not fully elucidated. This study aims to uncover the potential associations between LC and RA through an integrative approach of transcriptomics and genomics analysis.
methodsWe collected whole-genome expression data from patients with LC, RA, and healthy controls. Next-generation sequencing (NGS) was applied to analyze genomic variations in blood samples from RA patients, including those with comorbid LC and interstitial lung disease (ILD). Using bioinformatics tools, we identified differentially expressed genes (DEGs) and conducted an integrative analysis of pathways shared and specific to LC and RA.
resultsThe transcriptome analysis identified 1,051 DEGs common to both LC and RA, with distinct regulatory patterns. Among these, 441 genes were commonly upregulated, 345 were downregulated, and 265 exhibited opposite regulation between the two diseases. After integrating significant genomic mutation data, an additional 92 upregulated, 90 downregulated, and 41 oppositely regulated key genes were identified. Functional and enrichment analyses of these key genes revealed shared alterations in immune-related pathways, particularly the upregulation of viral response and immune signaling pathways, and the downregulation of T-cell receptor (TCR) signaling, T cell activation, and non-coding RNA metabolism. Furthermore, lymphocyte and leukocyte migration, as well as the positive regulation of programmed cell death, showed opposite regulation patterns between the two diseases. Laboratory tests also revealed changes in lymphocytes.
conclusionThis study delineates potential common mechanisms between LC and RA, suggesting that an enhanced viral response, attenuated TCR signaling, and reduced T cell activation in the peripheral system may represent shared pathological mechanisms, potentially contributing to the increased LC risk in RA patients. Conversely regulated DEGs may serve as novel biomarkers for pulmonary diseases. The changes in immune-related pathways and their potential association with lymphocyte activity provide new perspectives for understanding the relationship between LC and RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.